Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- National Cancer Institute (NCI)
- Study ID
- NCT03190915
- Phase
- PHASE2
- Status
- Active Not Recruiting
Conditions
- Juvenile Myelomonocytic Leukemia
- Neurofibromatosis Type 1
Eligibility Criteria
- Sex
- ALL
- Age
- 1 Month - 21 Years
- Healthy Volunteers
- Not accepted
Interventions
- Bone Marrow Aspiration and Biopsy — PROCEDUREUndergo bone marrow aspiration or biopsy
- Trametinib — DRUGGiven PO
Study Details
This phase II trial studies how well trametinib works in treating patients with juvenile myelomonocytic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Key Dates
- Start date
- Sep 9, 2018
- Status verified
- Jan 2026
- Primary completion
- Mar 31, 2023
- Completion
- Oct 3, 2026
Study Design
- Enrollment
- 10 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment (trametinib)Patients receive trametinib PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo a bone marrow aspiration or biopsy at baseline, on day 28 of cycles 1 and 2, at all subsequent odd numbered cycles, and at end of treatment.
Primary Outcome Measure
Objective Response [ Time Frame: 12 cycles (1 cycle = 28 days) ]
Locations (57)
Find similar trials in Birmingham, AL
Related Studies
- Familial Investigations of Childhood Cancer PredispositionRecruiting · St. Jude Children's Research Hospital · Memphis, Tennessee
- Myeloablative Allo HSCT With Related or Unrelated Donor for Heme DisordersPHASE2 · Recruiting · Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota
- HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell TransplantPHASE1 · Recruiting · Fred Hutchinson Cancer Center · Seattle, Washington
- CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCTRecruiting · Children's Hospital of Philadelphia · Philadelphia, Pennsylvania